Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010547
Filing Date
2025-05-15
Accepted
2025-05-15 08:35:30
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 565161
2 EX-31.1 ex31-1.htm EX-31.1 18197
3 EX-31.2 ex31-2.htm EX-31.2 17661
4 EX-32.1 ex32-1.htm EX-32.1 6855
5 EX-32.2 ex32-2.htm EX-32.2 7222
  Complete submission text file 0001641172-25-010547.txt   3420310

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20250331.xsd EX-101.SCH 28055
7 XBRL CALCULATION FILE ltrn-20250331_cal.xml EX-101.CAL 46040
8 XBRL DEFINITION FILE ltrn-20250331_def.xml EX-101.DEF 91219
9 XBRL LABEL FILE ltrn-20250331_lab.xml EX-101.LAB 229348
10 XBRL PRESENTATION FILE ltrn-20250331_pre.xml EX-101.PRE 187852
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 425555
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 25948945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)